Vallon Pharmaceuticals, Inc. (VLON): Price and Financial Metrics


Vallon Pharmaceuticals, Inc. (VLON): $0.27

0.00 (0.37%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

Add VLON to Watchlist
Sign Up

Industry: Biotech


Ranked

of

in industry

VLON Stock Price Chart Interactive Chart >

Price chart for VLON

VLON Price/Volume Stats

Current price $0.27 52-week high $2.78
Prev. close $0.27 52-week low $0.21
Day low $0.26 Volume 181,486
Day high $0.28 Avg. volume 470,749
50-day MA $0.28 Dividend yield N/A
200-day MA $0.48 Market Cap 3.41M

Vallon Pharmaceuticals, Inc. (VLON) Company Bio


Vallon Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of prescription drugs for central nervous system disorders. The company develops abuse-deterrent amphetamine immediate-release, an abuse-deterrent oral formulation of immediate-release dextroamphetamine for the treatment of attention-deficit/hyperactivity disorder and narcolepsy. It also develops ADMIR, an abuse deterrent formulation of Ritalin. The company was incorporated in 2018 and is based in Philadelphia, Pennsylvania.


VLON Latest News Stream


Event/Time News Detail
Loading, please wait...

VLON Latest Social Stream


Loading social stream, please wait...

View Full VLON Social Stream

Latest VLON News From Around the Web

Below are the latest news stories about VALLON PHARMACEUTICALS INC that investors may wish to consider to help them evaluate VLON as an investment opportunity.

Vallon Pharmaceuticals Reports Third Quarter 2022 Financial Results

PHILADELPHIA, PA, Nov. 03, 2022 (GLOBE NEWSWIRE) -- Vallon Pharmaceuticals, Inc. (NASDAQ: VLON), (“Vallon” or the “Company”), a clinical-stage biopharmaceutical company primarily focused on the development of novel drugs that are designed to deter abuse in the treatment of central nervous system (CNS) disorders, today reported its financial results for the quarter ended September 30, 2022.

GlobeNewswire | November 3, 2022

Vallon Pharmaceuticals reports Q3 results

Vallon Pharmaceuticals press release (VLON): Q3 Net loss was $1M for the quarter ended September 30, 2022.As of September 30, 2022, the company had cash, cash equivalents and…

Seeking Alpha | November 3, 2022

Vallon Pharmaceuticals Inc.’s Stock Gains 9.59%, But It May Still Be Worth Investing In.

The trading price of Vallon Pharmaceuticals Inc. (NASDAQ:VLON) floating higher at last check on Wednesday, October 05, closing at $0.33, 9.59% higher than its previous close. Traders who pay close attention to intraday price movement should know that it has been fluctuating between $0.26 and $0.34. In examining the 52-week price action we see that … Vallon Pharmaceuticals Inc.’s Stock Gains 9.59%, But It May Still Be Worth Investing In. Read More »

Stocks Register | October 5, 2022

Vallon Pharmaceuticals Reports Second Quarter 2022 Financial Results and Provides Corporate Update

PHILADELPHIA, PA, July 28, 2022 (GLOBE NEWSWIRE) -- Vallon Pharmaceuticals, Inc. (NASDAQ: VLON), (“Vallon” or the “Company”), a clinical-stage biopharmaceutical company primarily focused on the development of novel drugs that are designed to deter abuse in the treatment of central nervous system (CNS) disorders, today reported its financial results for the quarter ended June 30, 2022 and provided a corporate update.

GlobeNewswire | July 28, 2022

Vallon Pharmaceuticals reports Q2 results

Vallon Pharmaceuticals press release (VLON): Q2 net income was -$1.8M.Shares +2.36% PM.

Seeking Alpha | July 28, 2022

Read More 'VLON' Stories Here

VLON Price Returns

1-mo -6.90%
3-mo 4.53%
6-mo -35.08%
1-year -83.40%
3-year N/A
5-year N/A
YTD -6.90%
2022 -85.45%
2021 N/A
2020 N/A
2019 N/A
2018 N/A

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!


Page generated in 0.7143 seconds.